An Observational Study of Ezetimibe in Cardiac Transplant Recipients Receiving Calcineurin Inhibitors

Abstract

Ezetimibe was associated with lower LDL-C in cardiac transplant recipients either as combination therapy in patients with elevated LDL-C or as monotherapy, with a low frequency of adverse effects.

PCSK9 inhibitors in a renal transplant patient complicated with hepatitis B: A case report and literature review

“…Therefore, choosing the appropriate combination of statin and immunosuppressant is essential in post-transplant patients. As for the interaction between ezetimibe and immunosuppressants, it has been confirmed by previous studies that the combination of the two drugs is relatively safe and effective (22). In statin-intolerant patients or those still with dyslipidemia despite maximally tolerated statin treatment, alternative or additional therapy with ezetimibe may be considered (5).…”

Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation

“…Based on information from Refs. [ [1] , [2] , [3] , [4] , [5] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [32] , [33] , [34] , [35] , [36] , [37] , [44] , [45] , [46] , [47] , [48] , [49] , [50] ]. The elements of the figure were created using SERVIER MEDICAL ART (CC BY 4.0).…”

“…Ezetimibe effectively lowers LDL levels in patients after HTx and is safe. Moreover, the use of ezetimibe after HTx was found to be associated with a lower incidence of CAV [ 46 , 47 ]. PCSK9 inhibitors with intensive LDL reduction, reduction of coronary plaque thickness and increased lumen area, slow down the progression of CAV [ 48 ].…”